MAAT.PA - MAAT PHARMA
€8.80 -0.5 (-5.38%)
Updated: 11:50 May 5, 2024 ESTNext Session's AI Forecast
96.89%
Avg. Accuracy (AI)
€8.97
Next Week's AI Forecast
0%
Trend's Accuracy (AI)
€8.48
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0.21 | -0.09 | 0.5 | 0.16 | 0.05 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 0.93 | 1.77 | 2.9 | 2.88 | 2.58 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 100% | 100% | 88.1% | 94.85% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 9.41 | 2.51% | 9.18 | 0% | 9.18 | 16.94% | 7.85 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.69 | 14.53 | 2 | 40.83 |
|---|
MAAT PHARMA Technical Analysis News
MAAT PHARMA
70 Avenue Tony Garnier
Lyon 69007
France
33 4 28 29 14 00
https://www.maatpharma.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 52 |
Description
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Corporate Governance
MaaT Pharma SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.